他汀降脂治疗的安全性评价.pptVIP

* Muscular symptoms were reported by 10.5% of hypercholesterolaemic patients receiving high dosage statin therapy in the PRIMO study. This is considerably higher than the rate of 1–5% generally observed in clinical trials. The finding may be explained by the vigorous exclusion criteria employed in clinical trials in which patients groups at higher risk of muscular symptoms (such as the elderly, diabetic patients or patients with renal or hepatic impairment) are excluded. In addition, mild muscular symptoms without elevated CK levels are not generally reported in controlled studies. Patients